Review



myod expressing vectors  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Addgene inc myod expressing vectors
    Figure 3. <t>MyoD</t> <t>induces</t> <t>TSPCs</t> to myofibroblasts reprogramming in vitro. (A) and (B) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. (C) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). (D) PrestoBlue cell viability assay of MyoD-expressing or control TSPCs. ***p < 0.001. (E) Cellular length comparison and (F) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. (G) FACS gating strategy for control TSPCs and (H) myofibroblasts. (I) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. (J) Representative immunofluorescence images of MyoD-expressing TSPCs vs. control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.
    Myod Expressing Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/myod+expressing+vectors+cmv-+myod/CMV-MyoD+(Plasmid+%238398)/pm36411329-64-8-17
    Average 92 stars, based on 11 article reviews
    myod expressing vectors - by Bioz Stars, 2026-10
    92/100 stars

    Images

    1) Product Images from "Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts."

    Article Title: Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts.

    Journal: Scientific reports

    doi: 10.1038/s41598-022-24195-5

    Figure 3. MyoD induces TSPCs to myofibroblasts reprogramming in vitro. (A) and (B) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. (C) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). (D) PrestoBlue cell viability assay of MyoD-expressing or control TSPCs. ***p < 0.001. (E) Cellular length comparison and (F) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. (G) FACS gating strategy for control TSPCs and (H) myofibroblasts. (I) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. (J) Representative immunofluorescence images of MyoD-expressing TSPCs vs. control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.
    Figure Legend Snippet: Figure 3. MyoD induces TSPCs to myofibroblasts reprogramming in vitro. (A) and (B) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. (C) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). (D) PrestoBlue cell viability assay of MyoD-expressing or control TSPCs. ***p < 0.001. (E) Cellular length comparison and (F) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. (G) FACS gating strategy for control TSPCs and (H) myofibroblasts. (I) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. (J) Representative immunofluorescence images of MyoD-expressing TSPCs vs. control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.

    Techniques Used: In Vitro, Quantitative RT-PCR, Control, Expressing, Transfection, Microscopy, Viability Assay, Comparison, Software, Immunofluorescence, Staining

    Figure 5. In-vivo Wnt signaling modulation during adult tendon healing. (A) qRT-PCR Acta2 and Col3a1 quantification comparing 3 conditions: (1) control TSPCs (2) MyoD-expressing TSPCs (3) TSPCs + MyoD + Xav939 treatment. N = 3. (B) Representative H&E and Masson’s trichrome staining images of control and Xav939-treated tendons d28 after injury. N = 6 tendons/group. Scale bar, 40 μm, and (C) the corresponding Collagen deposition quantification. (D) Width quantification of control and Xav939-treated Achilles tendons (20 zones along 5 tendons/group). (E) Tendon thickness of control and Xav939-treated tendons (20 zones from 5 tendons/group). (F–I) Maximum force, yield elongation, stiffness and maximum tensile stress properties in the control and Xav939-treated groups d52 after injury. N = 6. Representative immunofluorescence staining images of α-SMA and VEGF.N = 5 tendons/group. Scale bar, 40 μm.
    Figure Legend Snippet: Figure 5. In-vivo Wnt signaling modulation during adult tendon healing. (A) qRT-PCR Acta2 and Col3a1 quantification comparing 3 conditions: (1) control TSPCs (2) MyoD-expressing TSPCs (3) TSPCs + MyoD + Xav939 treatment. N = 3. (B) Representative H&E and Masson’s trichrome staining images of control and Xav939-treated tendons d28 after injury. N = 6 tendons/group. Scale bar, 40 μm, and (C) the corresponding Collagen deposition quantification. (D) Width quantification of control and Xav939-treated Achilles tendons (20 zones along 5 tendons/group). (E) Tendon thickness of control and Xav939-treated tendons (20 zones from 5 tendons/group). (F–I) Maximum force, yield elongation, stiffness and maximum tensile stress properties in the control and Xav939-treated groups d52 after injury. N = 6. Representative immunofluorescence staining images of α-SMA and VEGF.N = 5 tendons/group. Scale bar, 40 μm.

    Techniques Used: In Vivo, Quantitative RT-PCR, Control, Expressing, Staining, Immunofluorescence

    Related Articles

    Transfection:

    Article Title: Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts
    Article Snippet: .. Neonatal TSPCs were transfected at 60–70% confluence with MyoD expressing vectors (CMV- MyoD , a gift from Andrew Lassar, Addgene plasmid # 8398) or with empty vectors (controls, CMV- MyoD restricted using EcoRI and ligated) using lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s recommendations. ..

    Expressing:

    Article Title: Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts
    Article Snippet: .. Neonatal TSPCs were transfected at 60–70% confluence with MyoD expressing vectors (CMV- MyoD , a gift from Andrew Lassar, Addgene plasmid # 8398) or with empty vectors (controls, CMV- MyoD restricted using EcoRI and ligated) using lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s recommendations. ..

    Plasmid Preparation:

    Article Title: Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts
    Article Snippet: .. Neonatal TSPCs were transfected at 60–70% confluence with MyoD expressing vectors (CMV- MyoD , a gift from Andrew Lassar, Addgene plasmid # 8398) or with empty vectors (controls, CMV- MyoD restricted using EcoRI and ligated) using lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s recommendations. ..



    Similar Products

    myod expressing vectors  (Addgene inc)
    92
    Addgene inc myod expressing vectors
    Figure 3. <t>MyoD</t> <t>induces</t> <t>TSPCs</t> to myofibroblasts reprogramming in vitro. (A) and (B) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. (C) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). (D) PrestoBlue cell viability assay of MyoD-expressing or control TSPCs. ***p < 0.001. (E) Cellular length comparison and (F) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. (G) FACS gating strategy for control TSPCs and (H) myofibroblasts. (I) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. (J) Representative immunofluorescence images of MyoD-expressing TSPCs vs. control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.
    Myod Expressing Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/myod+expressing+vectors+cmv-+myod/CMV-MyoD+(Plasmid+%238398)/pm36411329-64-8-17
    Average 92 stars, based on 1 article reviews
    myod expressing vectors - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    myod expressing vectors cmv- myod  (Addgene inc)
    90
    Addgene inc myod expressing vectors cmv- myod
    <t>MyoD</t> <t>induces</t> <t>TSPCs</t> to myofibroblasts reprogramming in vitro. ( A ) and (B ) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. ( C ) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). ( D ) PrestoBlue cell viability assay of MyoD -expressing or control TSPCs. ***p < 0.001. ( E ) Cellular length comparison and ( F ) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. ( G ) FACS gating strategy for control TSPCs and ( H ) myofibroblasts. ( I ) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. ( J ) Representative immunofluorescence images of MyoD-expressing TSPCs vs . control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.
    Myod Expressing Vectors Cmv Myod, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/myod+expressing+vectors+cmv-+myod/myod+expressing+vectors+cmv++myod/pmc09678895-39-8-19
    Average 90 stars, based on 1 article reviews
    myod expressing vectors cmv- myod - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    cmv myod expression vector  (Addgene inc)
    92
    Addgene inc cmv myod expression vector
    <t>MyoD</t> <t>induces</t> <t>TSPCs</t> to myofibroblasts reprogramming in vitro. ( A ) and (B ) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. ( C ) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). ( D ) PrestoBlue cell viability assay of MyoD -expressing or control TSPCs. ***p < 0.001. ( E ) Cellular length comparison and ( F ) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. ( G ) FACS gating strategy for control TSPCs and ( H ) myofibroblasts. ( I ) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. ( J ) Representative immunofluorescence images of MyoD-expressing TSPCs vs . control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.
    Cmv Myod Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/myod+expressing+vectors+cmv-+myod/CMV-MyoD+(Plasmid+%238398)/pmc06832012-691-1-6
    Average 92 stars, based on 1 article reviews
    cmv myod expression vector - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 3. MyoD induces TSPCs to myofibroblasts reprogramming in vitro. (A) and (B) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. (C) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). (D) PrestoBlue cell viability assay of MyoD-expressing or control TSPCs. ***p < 0.001. (E) Cellular length comparison and (F) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. (G) FACS gating strategy for control TSPCs and (H) myofibroblasts. (I) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. (J) Representative immunofluorescence images of MyoD-expressing TSPCs vs. control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.

    Journal: Scientific reports

    Article Title: Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts.

    doi: 10.1038/s41598-022-24195-5

    Figure Lengend Snippet: Figure 3. MyoD induces TSPCs to myofibroblasts reprogramming in vitro. (A) and (B) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. (C) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). (D) PrestoBlue cell viability assay of MyoD-expressing or control TSPCs. ***p < 0.001. (E) Cellular length comparison and (F) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. (G) FACS gating strategy for control TSPCs and (H) myofibroblasts. (I) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. (J) Representative immunofluorescence images of MyoD-expressing TSPCs vs. control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.

    Article Snippet: Neonatal TSPCs were transfected at 60–70% confluence with MyoD expressing vectors (CMV-MyoD, a gift from Andrew Lassar, Addgene plasmid # 8398) or with empty vectors (controls, CMV-MyoD restricted using EcoRI and ligated) using lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s recommendations.

    Techniques: In Vitro, Quantitative RT-PCR, Control, Expressing, Transfection, Microscopy, Viability Assay, Comparison, Software, Immunofluorescence, Staining

    Figure 5. In-vivo Wnt signaling modulation during adult tendon healing. (A) qRT-PCR Acta2 and Col3a1 quantification comparing 3 conditions: (1) control TSPCs (2) MyoD-expressing TSPCs (3) TSPCs + MyoD + Xav939 treatment. N = 3. (B) Representative H&E and Masson’s trichrome staining images of control and Xav939-treated tendons d28 after injury. N = 6 tendons/group. Scale bar, 40 μm, and (C) the corresponding Collagen deposition quantification. (D) Width quantification of control and Xav939-treated Achilles tendons (20 zones along 5 tendons/group). (E) Tendon thickness of control and Xav939-treated tendons (20 zones from 5 tendons/group). (F–I) Maximum force, yield elongation, stiffness and maximum tensile stress properties in the control and Xav939-treated groups d52 after injury. N = 6. Representative immunofluorescence staining images of α-SMA and VEGF.N = 5 tendons/group. Scale bar, 40 μm.

    Journal: Scientific reports

    Article Title: Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts.

    doi: 10.1038/s41598-022-24195-5

    Figure Lengend Snippet: Figure 5. In-vivo Wnt signaling modulation during adult tendon healing. (A) qRT-PCR Acta2 and Col3a1 quantification comparing 3 conditions: (1) control TSPCs (2) MyoD-expressing TSPCs (3) TSPCs + MyoD + Xav939 treatment. N = 3. (B) Representative H&E and Masson’s trichrome staining images of control and Xav939-treated tendons d28 after injury. N = 6 tendons/group. Scale bar, 40 μm, and (C) the corresponding Collagen deposition quantification. (D) Width quantification of control and Xav939-treated Achilles tendons (20 zones along 5 tendons/group). (E) Tendon thickness of control and Xav939-treated tendons (20 zones from 5 tendons/group). (F–I) Maximum force, yield elongation, stiffness and maximum tensile stress properties in the control and Xav939-treated groups d52 after injury. N = 6. Representative immunofluorescence staining images of α-SMA and VEGF.N = 5 tendons/group. Scale bar, 40 μm.

    Article Snippet: Neonatal TSPCs were transfected at 60–70% confluence with MyoD expressing vectors (CMV-MyoD, a gift from Andrew Lassar, Addgene plasmid # 8398) or with empty vectors (controls, CMV-MyoD restricted using EcoRI and ligated) using lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s recommendations.

    Techniques: In Vivo, Quantitative RT-PCR, Control, Expressing, Staining, Immunofluorescence

    MyoD induces TSPCs to myofibroblasts reprogramming in vitro. ( A ) and (B ) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. ( C ) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). ( D ) PrestoBlue cell viability assay of MyoD -expressing or control TSPCs. ***p < 0.001. ( E ) Cellular length comparison and ( F ) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. ( G ) FACS gating strategy for control TSPCs and ( H ) myofibroblasts. ( I ) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. ( J ) Representative immunofluorescence images of MyoD-expressing TSPCs vs . control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.

    Journal: Scientific Reports

    Article Title: Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts

    doi: 10.1038/s41598-022-24195-5

    Figure Lengend Snippet: MyoD induces TSPCs to myofibroblasts reprogramming in vitro. ( A ) and (B ) Acta2 and Col3a1 qRT-PCR quantification comparing 3 conditions: “control TSPCs”, “MyoD-expressing TSPCs (14 days after transfection)” and “TSPCs + MyoD + Xav939 treatment”. N = 3. ( C ) Representative morphological change 14 days after MyoD expression under inverted (scale bar, 50 μm) or scanning electron microscope (scale bar, 25 μm). ( D ) PrestoBlue cell viability assay of MyoD -expressing or control TSPCs. ***p < 0.001. ( E ) Cellular length comparison and ( F ) width (Control vs. MyoD-expressing TSPCs 14 days after transfection) using image J software, 20 microscopic fields, **p < 0.01. ( G ) FACS gating strategy for control TSPCs and ( H ) myofibroblasts. ( I ) FACS based quantification of ACTA2 + cells. *p < 0.05. N = 3. ( J ) Representative immunofluorescence images of MyoD-expressing TSPCs vs . control TSPCs stained for VEGF (green) and α-SMA (red). N = 3. Scale bar, 20 μm.

    Article Snippet: Neonatal TSPCs were transfected at 60–70% confluence with MyoD expressing vectors (CMV- MyoD , a gift from Andrew Lassar, Addgene plasmid # 8398) or with empty vectors (controls, CMV- MyoD restricted using EcoRI and ligated) using lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s recommendations.

    Techniques: In Vitro, Quantitative RT-PCR, Control, Expressing, Transfection, Microscopy, Viability Assay, Comparison, Software, Immunofluorescence, Staining

    In-vivo Wnt signaling modulation during adult tendon healing. ( A ) qRT-PCR Acta2 and Col3a1 quantification comparing 3 conditions: (1) control TSPCs (2) MyoD-expressing TSPCs (3) TSPCs + MyoD + Xav939 treatment. N = 3. ( B ) Representative H&E and Masson’s trichrome staining images of control and Xav939-treated tendons d28 after injury. N = 6 tendons/group. Scale bar, 40 μm, and ( C ) the corresponding Collagen deposition quantification . ( D ) Width quantification of control and Xav939-treated Achilles tendons (20 zones along 5 tendons/group). ( E ) Tendon thickness of control and Xav939-treated tendons (20 zones from 5 tendons/group). ( F–I ) Maximum force, yield elongation, stiffness and maximum tensile stress properties in the control and Xav939-treated groups d52 after injury. N = 6. Representative immunofluorescence staining images of α-SMA and VEGF.N = 5 tendons/group. Scale bar, 40 μm.

    Journal: Scientific Reports

    Article Title: Mohawk impedes angiofibrosis by preventing the differentiation of tendon stem/progenitor cells into myofibroblasts

    doi: 10.1038/s41598-022-24195-5

    Figure Lengend Snippet: In-vivo Wnt signaling modulation during adult tendon healing. ( A ) qRT-PCR Acta2 and Col3a1 quantification comparing 3 conditions: (1) control TSPCs (2) MyoD-expressing TSPCs (3) TSPCs + MyoD + Xav939 treatment. N = 3. ( B ) Representative H&E and Masson’s trichrome staining images of control and Xav939-treated tendons d28 after injury. N = 6 tendons/group. Scale bar, 40 μm, and ( C ) the corresponding Collagen deposition quantification . ( D ) Width quantification of control and Xav939-treated Achilles tendons (20 zones along 5 tendons/group). ( E ) Tendon thickness of control and Xav939-treated tendons (20 zones from 5 tendons/group). ( F–I ) Maximum force, yield elongation, stiffness and maximum tensile stress properties in the control and Xav939-treated groups d52 after injury. N = 6. Representative immunofluorescence staining images of α-SMA and VEGF.N = 5 tendons/group. Scale bar, 40 μm.

    Article Snippet: Neonatal TSPCs were transfected at 60–70% confluence with MyoD expressing vectors (CMV- MyoD , a gift from Andrew Lassar, Addgene plasmid # 8398) or with empty vectors (controls, CMV- MyoD restricted using EcoRI and ligated) using lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s recommendations.

    Techniques: In Vivo, Quantitative RT-PCR, Control, Expressing, Staining, Immunofluorescence